Development of the conceptual framework for the Eye-Drop Satisfaction Questionnaire (EDSQ©) in glaucoma using a qualitative study

BMC Health Services Research

Volumn 7, Issue , 2007, Pages

  Nordmann, Jean Philippe ^a   Denis, Philippe ^b   Vigneux, Marc ^c   Trudeau, Elyse ^c   Guillemin, Isabelle ^c   Berdeaux, Gilles ^d,e  

^a CENTRE HOSPITALIER NATIONAL D OPHTALMOLOGIE DES QUINZE VINGTS   (France)

^b EDOUARD HERRIOT HOSPITAL   (France)

^c MAPI VALUES   (United States)

^d Bioinformatique et Chimie Moléculaire   (France)

^e Alcon France   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EYE DROPS; ANTIHYPERTENSIVE AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONCEPTUAL FRAMEWORK; DATA ANALYSIS; DOCTOR PATIENT RELATION; EYE DROP SATISFACTION QUESTIONNAIRE; FEMALE; GLAUCOMA; HUMAN; INFORMATION RETRIEVAL; INTERVIEW; INTRAOCULAR HYPERTENSION; MALE; OPEN ANGLE GLAUCOMA; PATIENT ASSESSMENT; PATIENT COMPLIANCE; PATIENT SATISFACTION; QUALITATIVE ANALYSIS; QUESTIONNAIRE; RISK ASSESSMENT; TREATMENT INDICATION; ECONOMICS; FRANCE; MIDDLE AGED; MOTIVATION; PATIENT EDUCATION; PSYCHOLOGICAL ASPECT; QUALITATIVE RESEARCH; RISK FACTOR; SOCIOECONOMICS; STATISTICS; UNITED KINGDOM;

AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; FEMALE; FRANCE; GLAUCOMA, OPEN-ANGLE; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; MOTIVATION; OPHTHALMIC SOLUTIONS; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT SATISFACTION; PHYSICIAN-PATIENT RELATIONS; QUALITATIVE RESEARCH; QUESTIONNAIRES; RISK FACTORS; SOCIOECONOMIC FACTORS;

EID: 34548545104     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-7-124     Document Type: Article

References (36)

1. Self-reported visual impairment and mortality: a French nationwide perspective. G Berdeaux A Brézin F Fagnani A Lafuma M Mesbah, Ophthalmic Epidemiol 2007 14 80 87 10.1080/09286580600899691 17464855
2. Magnitude and causes of blindness: Sources and limitations of data. H Goldstein, Clinical ophthalmology. Volume 2 Philadelphia, USA: Lippincott Company, Freemann JS, 1990 5 1 10
3. Prevalence and burden of self-reported blindness, low vision, and visual impairment in the French community: a nationwide survey. AP Brézin A Lafuma F Fagnani M Mesbah G Berdeaux, Arch Ophthalmol 2005 123 1117 1124 10.1001/archopht.123.8.1117 16087847
4. Prevalence of Open-Angle Glaucoma among adults in the United States. DS Friedman RC Wolfs BJ O'Colmain BE Klein HR Taylor S West MC Leske P Mitchell N Congdon J Kempen Eye Diseases Prevalence Research Group, Arch Ophthalmol 2004 122 532 538 10.1001/archopht.122.7.1019 15078671
5. The age distribution of primary open angle glaucoma. MW Tuck RP Crick, Ophthalmic Epidemiol 1998 5 173 183 10.1076/opep.5.4.173.4192 9894803
6. Office visits for glaucoma: United States, 1991-1992. SM Schappert, Adv Data 1995 262 1 14
7. Deaths and disease burden by cause: global burden of disease estimates for 2001 by world bank country groups. C Mathers A Lopez C Stein D Ma Fat C Rao M Inoue K Shibuya N Tomijima C Bernard H Xu, http://www.dcp2.org/file/33/wp18. pdf
8. Evaluation of non-medical costs associated with visual impairment in four European countries: France, Italy, Germany and the United Kingdom. A Lafuma A Brézin S Lopatriello K Hieke J Hutchinson V Mimaud G Berdeaux, Pharmacoeconomics 2006 24 193 205 10.2165/00019053-200624020-00007 16460138
9. The impact of glaucoma on the quality of life of patients in Norway. II. Patient response correlated to objective data. T Odberg JE Jakobsen SJ Hultgren R Halseide, Acta Ophthalmol Scand 2001 79 121 124 10.1034/j.1600-0420.2001. 079002121.x 11284747
10. Evaluation of quality of life for patients with glaucoma. G Spaeth J Walt J Keener, Am J Ophthalmol 2006 141 3 14 10.1016/j.ajo.2005.07.075
11. Blindness, low vision and other handicaps as risk factors attached to institutional residence. A Brézin A Lafuma F Fagnani M Mesbah G Berdeaux, Br J Ophthalmol 2004 88 1330 1337 10.1136/bjo.2003.039180 15377561
12. Nonmedical economic consequences attributable to visual impairment: A nation-wide approach in France. A Lafuma A Brézin F Fagnani V Mimaud M Mesbah G Berdeaux, Eur J Health Econ 2006 7 158 164 10.1007/s10198-006-0346-1 16850334
13. Psychometric validation of the National Eye Institute Visual Function Questionnaire - 25 (NEI VFQ-25) French version: in a population of patients treated for ocular hypertension and glaucoma. JP Nordmann M Viala K Sullivan B Arnoult G Berdeaux, Pharmacoeconomics 2004 22 197 206 10.2165/00019053- 200422030-00005 14871166
14. Ocular pressure and visual fields. A ten-year follow-up study. MF Armaly, Arch Ophthalmol 1969 81 25 40 5763217
15. Untreated ocular hypertension. A long-term prospective study. Y Kitazawa T Horie S Aoki M Suzuki K Nishioka, Arch Ophthalmol 1977 95 1180 1184 880076
16. Comparaison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group, Am J Ophthalmol 1998 126 487 497 10.1016/S0002-9394(98)00223-2 9780093
17. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. A Heijl MC Leske B Bengtsson L Hyman B Bengtsson M Hussein Early Manifest Glaucoma Trial Group, Arch Ophthalmol 2002 120 1268 1279 12365904
18. The Ocular Hypertension Treatment Study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. MA Kass DK Heuer EJ Higginbotham CA Johnson JL Keltner JP Miller RK Parrish 2nd MR Wilson MO Gordon, Arch Ophthalmol 2002 120 701 713 12049574
19. The advanced glaucoma intervention study (AGIS): 7. The relationship between control of intra-ocular pressure and visual field deterioration. The AGIS investigators, Am J Ophthalmol 2000 130 429 440 10.1016/S0002-9394(00) 00538-9 11024415
20. Risk factors for noncompliance with glaucoma follow-up visits in a residents' eye clinic. O Kosoko HA Quigley S Vitale C Enger L Kerrigan JM Tielsch, Ophthalmology 1998 105 2105 2111 10.1016/S0161-6420(98)91134-4 9818613
21. Patient and ophthalmologist attitudes concerning compliance and dosing in glaucoma treatment. WC Stewart AG Konstas N Pfeiffer, J Ocul Pharmacol Ther 2004 20 461 469 10.1089/jop.2004.20.461 15684806
22. Terminology and guidelines for glaucoma. The European Glaucoma Society, 2 http://www.eugs.org/ebook.asp
23. Medical outcomes of glaucoma therapy from a nationwide representative survey. P Denis A Lafuma G Berdeaux, Clin Drug Investig 2004 24 343 352 10.2165/00044011-200424060-00004 17516721
24. Vision related quality of life and topical glaucoma treatment side effects. JP Nordmann N Auzanneau S Ricard G Berdeaux, Health Qual Life Outcomes 2003 1 1 9 12605709 10.1186/1477-7525-1-75
25. Patient-reported behaviour and problems in using glaucoma medications. B Sleath AL Robin D Covert JE Byrd G Tudor B Svarstad, Ophthalmology 2006 113 431 436 10.1016/j.ophtha.2005.10.034 16458967
26. Compliance barriers in glaucoma: a systematic classification. JC Tsai CA McClure SE Ramos DG Schlundt JW Pichert, J Glaucoma 2003 12 393 398 10.1097/00061198-200310000-00001 14520147
27. The impact of patient adherence on health outcomes for patients with chronic disease in the medical outcomes study. RD Hays RL Kravitz RM Mazel CD Sherbourne MR DiMatteo WH Rogers S Greenfield, J Behav Med 1994 17 347 360 10.1007/BF01858007 7966257
28. Linking service quality, customer satisfaction, and behavioral intention. AG Woodside LL Frey RT Day, J Health Care Mark 1989 9 5 17 10304174
29. The clinical validity of the treatment satisfaction survey for intraocular pressure in ocular hypertensive and glaucoma patients. DG Day ED Sharpe MJ Atkinson JA Stewart WC Stewart, Eye 2006 20 583 590 10.1038/sj.eye.6701932 15933751
30. Patient-Reported Outcomes to support medical product labelling claims. DL Patrick LB Burke JH Powers JA Scott EP Rock S Dawisha R O'Neill D Kennedy, Unpublished data.
31. The Grounded Theory. K Charmaz, Rethinking methods in psychology London, Sage, Smith JA, Harré R, Van Langenhove L, 1995 27 49
32. Early Conceptual and linguistic development of a patient and partner Treatment Satisfaction Scale (TSS) for erectile dysfunction. M Kubin E Trudeau K Gondek E Seignobos AR Fugl-Meyer, Eur Urol 2004 46 768 775 10.1016/j.eururo. 2004.08.001 15548446
33. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. MJ Atkinson A Sinha SL Hass SS Colman RN Kumar M Brod CR Rowland, Health Qual Life Outcomes 2004 2 12 14987333 10.1186/1477-7525-2-12
34. A new measure of patient satisfaction with ocular hypotensive medications: The Treatment Satisfaction Survey for Intraocular Pressure (TSS-IOP). MJ Atkinson WC Stewart JM Fain JA Stewart R Dhawan E Mozaffari J Lohs, Health Qual Life Outcomes 2003 1 1 67 14617372 10.1186/1477-7525-1-67
35. The significance of saturation. JM Morse, Qual Health Res 1995 5 145 147
36. How many interviews are enough? An experiment with data saturation and variability. G Guest A Bunce L Johnson, Field Methods 2006 18 59 82 10.1177/1525822X05279903